the sun malaysia ipaper logo 150x150
Friday, July 3, 2026
27.5 C
Kuala Lumpur
the sun malaysia ipaper logo 150x150

YXPM records 14.1% growth in profit after tax

KUALA LUMPUR: YX Precious Metals Bhd (YXPM or the Group), a wholesaler and manufacturer specialising in gold jewellery, today announced its third quarter results for the financial year ending Dec 31, 2023 (Q3FYE2023).

The Group delivered a profit after tax (PAT) of RM1.9 million on the back of a revenue of RM53.6 million. The wholesale segment itself recorded a revenue of RM42.0 million. The design and manufacture segment generated RM11.6 million for the quarter under review, leaping by over 100% from RM5.3 million in the corresponding quarter last year.

For the nine-month period ended Sept 30, 2023, YXPM recorded a 14.1% growth, year on year, in PAT to RM7.4 million on the back of a revenue of RM178.0 million. The PAT growth was supported through lower administrative expenses, as well as higher sales generated from the design and manufacture segment of RM32.8 million, representing an increase of over 100%, year on year. The spike in the segment’s revenue in turn was attributed to higher demand of gold jewelleries from Peninsular Malaysia.

Commenting on the results, YXPM managing director Ng Sheau Chyn said, “The operating environment remains challenging as recent geopolitical tensions and the impending high value goods tax remain a concern. Nonetheless we remain committed on our strategies to widen our range of gold jewellery offerings to our customers, through the utilisation of our IPO proceeds by obtaining new machineries and equipment whilst we carry out the expansion and upgrading of our facilities. Overall, we remain optimistic of the Group’s ability to deliver a satisfactory financial performance for 2023.”

STAY AHEAD OF THE CURVE

Join our community for instant updates and exclusive content.

Join Telegram Channel

Related


spot_img

Latest News

Addressing medical inflation

Consumers are struggling as medical insurance premiums surge, with over 340,000 dropping coverage amid calls for price regulation and stronger public healthcare

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations

TAIPEI, TAIWAN - Media OutReach Newswire - 2 July 2026 - Bora Pharmaceuticals Co., Ltd. ("Bora" or "Bora Group"; TWSE: 6472; OTCQX: BORAY) today announced the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. (NASDAQ: MGNX) including its biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for total consideration of US $122.5 million through its wholly owned subsidiary Bora Biologics USA, LLC.. Upon closing, Bora signed a long-term CDMO Service Agreement with MacroGenics.

Most Viewed

spot_img
WC26

World Cup 2026

Updates, Fixtures, Results & Standings